In prostate cancer, elevated PD-L1 expression was significantly correlated with CD163+ TAM invasion and Gleason score; furthermore, patients with high levels of CD163+ TAM and PD-L1 expression had shorter biochemical recurrence-free survival [72]. Here, CD163 is linked to prostate cancer.